MIAMI--(BUSINESS WIRE)--Brickell Biotech, Inc. (“Brickell”), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative therapeutics to satisfy current unmet medical needs in the global dermatology markets, today announced the signing of an exclusive license and development agreement for BBI-4000 with Kaken Pharmaceutical Co., Ltd. (“Kaken”), a top-tier specialty pharmaceutical company in Japan with strong experience in developing and commercializing novel dermatological drugs.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
